Press Releases Shanghai Junshi Biosciences Co., Ltd.

Equities

1877

CNE100003FF7

Delayed Hong Kong S.E. Other stock markets 10:51:24 2024-05-12 pm EDT			5-day change	1st Jan Change
12.62 ^HKD	0.00%		+1.62%	-35.49%

Apr. 29	Shanghai Junshi Biosciences Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Apr. 25	Shanghai Junshi Biosciences Receives Hong Kong Approval for Cancer Drug Toripalimab	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Junshi Biosciences Announces NDA Acceptance in Hong Kong for Toripalimab	Apr. 24	GL
Junshi Biosciences Announces Approval of the sNDA for Toripalimab for the 1st-Line Treatment of Renal Cancer	Apr. 07	AQ
Junshi Biosciences Announces Approval of the sNDA for Toripalimab for the 1st-Line Treatment of Renal Cancer	Apr. 07	GL
Junshi Biosciences Announces 2023 Full Year Financial Results and Provides Corporate Updates	Mar. 29	GL
Junshi Biosciences Announces Toripalimab’s NDA Accepted by the Singapore Health Sciences Authority	Feb. 01	GL
Junshi Biosciences Announces JAMA Publication of Results from NEOTORCH, a Randomized Phase 3 Trial of Perioperative Toripalimab plus Chemotherapy for Patients with Resectable Non-Small Cell Lung Cancer	Jan. 17	GL
Junshi Biosciences Announces Publication of Results from TORCHLIGHT, a Randomized Phase 3 Trial of Toripalimab for the Treatment of Metastatic or Recurrent Triple-negative Breast Cancer in Nature Medicine	Jan. 09	GL
Junshi Biosciences Announces Approval of the Supplemental New Drug Application for Toripalimab as Perioperative Treatment for Resectable NSCLC Patients	Jan. 02	AQ
Junshi Biosciences Announces Approval of the Supplemental New Drug Application for Toripalimab as Perioperative Treatment for Resectable NSCLC Patients	Jan. 02	GL
Junshi Biosciences Announces New Chemical Entity Application for Toripalimab Accepted by Australia’s TGA	Dec. 01	AQ
Junshi Biosciences Announces New Chemical Entity Application for Toripalimab Accepted by Australia’s TGA	Dec. 01	GL
Coherus and Junshi Biosciences Announce Publication of Positive Final Overall Survival Results of JUPITER-02, a Phase 3 Trial Evaluating LOQTORZI as Treatment for Nasopharyngeal Carcinoma	Nov. 29	AQ
Junshi Biosciences Announces Lancet Infectious Diseases Publication of Results from the 2nd Phase 3 Study of VV116 for Treating COVID-19	Nov. 22	GL
FDA Approves LOQTORZI In All Lines Of Treatment For Recurrent Or Metastatic Nasopharyngeal Carcinoma	Nov. 03	AQ
Coherus and Junshi Biosciences Announce FDA Approval of LOQTORZI in All Lines of Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma	23-10-30	AQ
Junshi Biosciences Presents 11 Clinical Trials of Toripalimab at the ESMO Congress 2023	23-10-27	GL
Junshi Biosciences Announces 2023 Interim Financial Results and Provides Corporate Updates	23-08-30	GL
Junshi Biosciences Announces Acceptance of the Supplemental New Drug Application for Toripalimab as the First-line Treatment of Extensive-stage Small Cell Lung Cancer	23-07-19	GL
Junshi Biosciences Announces Acceptance of the Supplemental New Drug Application for Toripalimab	23-07-11	GL
Junshi Biosciences Announces Initiation of Phase 3 Study of Tifcemalimab plus Toripalimab for Treatment of Limited-stage Small Cell Lung Cancer	23-06-29	GL

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Shanghai Junshi Biosciences Co., Ltd.

Equities

1877

CNE100003FF7

Press Releases

Filters